Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib

Tiseo, M.; Ippolito, M.; Scarlattei, M.; Spadaro, P.; Cosentino, S.; Latteri, F.; Ruffini, L.; Bartolotti, M.; Bortesi, B.; Fumarola, C.; Caffarra, C.; Cavazzoni, A.; Alfieri, R. R.; Petronini, P. G.; Bordonaro, R.; Bruzzi, P.; Ardizzoni, A.; Soto Parra, H.

doi:10.1007/s00280-013-2356-x

Background: [18F]fluorodeoxyglucose (FDG)-PET is being evaluated as a tool for the early detection of response to various targeted agents in solid tumors. The aim of this study was to evaluate the predictive value of PET response after 2 days of erlotinib in unselected pretrated patients with stage IV NSCLC. Patients and methods: FDG-PET/CT scans were conducted at baseline and after 2 days of erlotinib, with a CT evaluation performed at baseline and after 45-60 days of therapy. PET responses were evaluated by quantitative changes on SUVmax tumor/non-tumor ratio and classified according to EORTC criteria. PET responses were compared with RECIST responses and related to progression-free (PFS) and overall (OS) survival. Erlotinib effects on glucose uptake were also studied in a panel of NSCLC cell lines. Results: Fifty-three patients were enrolled. At 2 days of erlotinib, 20 (38 %) patients showed partial metabolic response (PMR), 25 (47 %) had stable metabolic disease (SMD) and 8 (15 %) had progressive metabolic disease (PMD). All patients with PMD had confirmed RECIST progression at 45-60 days. Patients with early PMR and SMD had significantly longer PFS (p < 0.001 and p = 0.001, respectively) and OS (p = 0.001 for both) than PMD patients. Conclusions: FDG-PET assessment after 2 days of erlotinib could be useful to identify early resistent patients and to predict survival in unselected NSCLC pretreated population. © 2013 Springer-Verlag.

Titolo:	Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib
Autori interni:	Tiseo M. Ippolito M. Scarlattei M. Spadaro P. Cosentino S. Latteri F. Ruffini L. Bartolotti M. Bortesi B. Fumarola C. Caffarra C. Cavazzoni A. Alfieri R. R. Petronini P. G. Bordonaro R. Bruzzi P. Ardizzoni A. SOTO PARRA, HECTOR mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2014
Rivista:	CANCER CHEMOTHERAPY AND PHARMACOLOGY
Handle:	http://hdl.handle.net/20.500.11769/369769
Appare nelle tipologie:	1.1 Articolo in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/20.500.11769/369769

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

File in questo prodotto: